ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2017
Ureaplasma parvum causes hyperammonemia in a pharmacologically immunocompromised murine model.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Hyperammonemia After Lung Transplantation: Systematic Review and a Mini Case Series.Transplant international : official journal of the European Society for Organ Transplantation · 2022Pooled it
- Comparative efficacy of levofloxacin, azithromycin, and doxycycline prophylaxis and treatment in an experimentalAntimicrobial agents and chemotherapy · 2025Article
- Hyperammonaemia syndrome in disseminatedBMJ case reports · 2022Article
- Flurofamide Prevention and Treatment ofMicrobiology spectrum · 2022Article
- Contribution of Uremia toMicrobiology spectrum · 2022Article
- Ureaplasma parvum meningitis following atypical choroid plexus papilloma resection in an adult patient: a case report and literature review.BMC infectious diseases · 2021Review
- Impact of Screening and Treatment of Ureaplasma species on Hyperammonemia Syndrome in Lung Transplant Recipients: A Single Center Experience.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Review: immunosuppression for the lung transplant patient.Journal of thoracic disease · 2021Review
- A novel bioreactor for the stable growth of Ureaplasma parvum and Ureaplasma urealyticum.Journal of microbiological methods · 2021Article
- Hyperammonemia syndrome due to Ureaplasma infection after liver-kidney transplant.Transplant infectious disease : an official journal of the Transplantation Society · 2020Article
- NeonatalTranslational pediatrics · 2020Article
- Hyperammonemia Post Lung Transplantation: A Review.Clinical medicine insights. Circulatory, respiratory and pulmonary medicine · 2020Review
- An Update in Antimicrobial Therapies and Infection Prevention in Pediatric Lung Transplant Recipients.Paediatric drugs · 2018Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
A relationship between hyperammonemia and Ureaplasma infection has been shown in lung transplant recipients. We have demonstrated that Ureaplasma urealyticum causes hyperammonemia in a novel immunocompromised murine model. Herein, we determined whether Ureaplasma parvum can do the same. Male C3H mice were given mycophenolate mofetil, tacrolimus, and prednisone for 7 days, and then challenged with U. parvum intratracheally (IT) and/or intraperitoneally (IP), while continuing immunosuppression over 6 days. Plasma ammonia concentrations were determined and compared using Wilcoxon rank-sum tests. Plasma ammonia concentrations of immunosuppressed mice challenged IT/IP with spent broth (median, 188 μmol/L; range, 102-340 μmol/L) were similar to those of normal (median, 226 μmol/L; range, 154-284 μmol/L, p > 0.05), uninfected immunosuppressed (median, 231 μmol/L; range, 122-340 μmol/L, p > 0.05), and U. parvum IT/IP challenged immunocompetent (median, 226 μmol/L; range, 130-330 μmol/L, p > 0.05) mice. Immunosuppressed mice challenged with U. parvum IT/IP (median 343 μmol/L; range 136-1,000 μmol/L) or IP (median 307 μmol/L; range 132-692 μmol/L) had higher plasma ammonia concentrations than those challenged IT/IP with spent broth (p < 0.001). U. parvum can cause hyperammonemia in pharmacologically immunocompromised mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.